Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan G Duda

Showing results (221-230 of 261) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular CarcinomaLipika Goyal, Hui Zheng, Thomas A Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Science Translational Medicine|October 14, 2016
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastasesNuh N Rahbari, Dmitriy Kedrin, Joao Incio, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2016
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophagesTeresa E Peterson, Nathaniel D Kirkpatrick, Yuhui Huang, et al.
Cancer Biomarkers : Section a of Disease Markers|September 13, 2024
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with NivolumabYehia I Mohamed, Sunyoung S Lee, Tarik Demir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in ObesityJoao Incio, Josh Tam, Nuh N Rahbari, et al.
Journal for Immunotherapy of Cancer|November 25, 2020
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinomaKohei Shigeta, Aya Matsui, Hiroto Kikuchi, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2020
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation OncologistsAlice Y Ho, Jean L Wright, Rachel C Blitzblau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Pageof 27

Showing results (221-230 of 261) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular CarcinomaLipika Goyal, Hui Zheng, Thomas A Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett, Dan G Duda, Emmanuelle di Tomaso, et al.
Science Translational Medicine|October 14, 2016
Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastasesNuh N Rahbari, Dmitriy Kedrin, Joao Incio, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2016
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophagesTeresa E Peterson, Nathaniel D Kirkpatrick, Yuhui Huang, et al.
Cancer Biomarkers : Section a of Disease Markers|September 13, 2024
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with NivolumabYehia I Mohamed, Sunyoung S Lee, Tarik Demir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2016
PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in ObesityJoao Incio, Josh Tam, Nuh N Rahbari, et al.
Journal for Immunotherapy of Cancer|November 25, 2020
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinomaKohei Shigeta, Aya Matsui, Hiroto Kikuchi, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2020
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation OncologistsAlice Y Ho, Jean L Wright, Rachel C Blitzblau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II studyAndrew X Zhu, Dushyant V Sahani, Dan G Duda, et al.
Pageof 27